Trending...
- Cummings Graduate Institute for Behavioral Health Studies Celebrates 10 Years of Excellence in Integrated Behavioral Healthcare Education
- Kuester Management Group Breaks Down HOA Management Agreement Guidelines
- Powerful Leadership Transition to Optimize Highly Promising AI Platform RenovaroCube for Multi-Cancer Early Detection & Monitoring: Stock Symbol: RENB
EXCELSIOR, Minn. - ncarol.com -- NeuraWorx Medical Technologies, Inc., a neurotechnology therapeutics company, announced today a partnership with prominent neuroscience venture builder and fund, Corundum Neuroscience. As part of the collaboration, Corundum will provide resources, including the initial investment in a NeuraWorx seed funding round, aimed at advancing product development and initiating a clinical feasibility study to explore the efficacy and safety of its Cerebrovascular Pacing SystemTM novel technology.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on ncarol.com
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on ncarol.com
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on ncarol.com
- Balam and Transfera Unveil the World's First Remittance-as-a-Service Platform
- Minor Use Foundation Awarded $2M Grant from Assisting Specialty Crop Exports Initiative
- AI-driven money-saving tips: Black Friday shopping guide for 2024
- myStaze: Revolutionizing Live Music Streaming in the U.S. – Artists Earn 90% of Ticket Sales!
- ICONS OF ORIGINALITY: VALVOLINE™ GLOBAL OPERATIONS UNITES ASTON MARTIN ARAMCO'S JESSICA HAWKINS AND NASCAR HALL OF FAMER JEFF GORDON FOR HISTORIC DRIVER MATCHUP IN CHARLOTTE
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on ncarol.com
- Crosby Tatum's "The People, United" heads to Georgia & New York City during 2024 US General Election Season
- Terror Strikes - not if, but when, and Fight? Flight? Third option
- X3 Build Shares 4 Essential Questions to Ask a Custom Home Builder in Santa Monica Before Hiring Them
- Hel Todd Jr. Celebrate His Birthday! – A Special Opportunity to Bless a Young Boy in Need
- LIBRE's Cesar Grajales Tops the #1 Rankings for Spanish Radio Stations in Miami
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
Source: NeuraWorx Medical Technologies, Inc.
0 Comments
Latest on ncarol.com
- Arthur Murray Dance Studio of Denville: Dance Your Way to Joy and Confidence in North Jersey
- Arthur Murray Dance Studio of Napa: Discover the Joy of Dance in Wine Country
- Not Sure If Your Work Makes a Difference? Hear What God Is Saying to You Today
- Hillsborough Gallery of Arts Previews Orange County Artists Guild Studio Tour
- Better Termite & Pest Control Marks 56 Years of Fall Pest Protection
- Halloween Spending Surge Drives U.S. Holiday Economy Growth in 2024
- People are Having Millions of Conversations with Friends and Family About Voting in the 2024 Election
- 5 Questions to Always Ask Roofing Companies in Memphis Before Hiring Them
- David Boland, Inc. Awarded $42.6M Construction Contract With U.S. Army Corps of Engineers, Wilmington
- Lifesaving Portable, AI Augmented Cardiac Monitoring Technology Poised for Commercial Launch Under New Industry Leader: Heartbeam: Stock Symbol: BEAT
- KeysCaribbean Extends Advance Purchase Rate Discount Offer
- Kenneth Carnesi, Sr. COO Anaptyx Honored with 2024 Global Recognition Award
- Mount Dora Craft Fair and Plant Festival set to go on after hurricane hit
- ConverzAI Accelerates Industry Transformation with Groundbreaking AI-Powered Virtual Recruiters
- Cummings Graduate Institute for Behavioral Health Studies Celebrates 10 Years of Excellence in Integrated Behavioral Healthcare Education
- Significant Leaps Redefining Digital Commerce Connecting Merchants & Shoppers Rewarding Customers with Instant Cash Rebates (Stock Symbol: STBX)
- Michele Vreeland Explores the Supernatural with Haunting New Single 'Soul Collector,' Releasing October 25th, Just in Time for Halloween
- Nadia C. Vanderhall Named to Johnson C. Smith University's Forty Under 40, Class of 2024
- Jude Madrigal releases his first children's book, "The Trick-or-Treat Tree and the First Halloween."
- Powerful Leadership Transition to Optimize Highly Promising AI Platform RenovaroCube for Multi-Cancer Early Detection & Monitoring: Stock Symbol: RENB